UAE-based healthtech company BioSapien has extended its pre-Series A round to $7 million, welcoming new investment from Golden Gate Ventures, marking the first deployment from its dedicated MENA Fund. This follows the company’s earlier $5.5 million round in December, led by Global Ventures and Dara Holdings.
Founded in 2018 by Khatija Ali, BioSapien is the developer of MediChip™, a 3D-printed, slow-release drug delivery platform that attaches to tissue and delivers medication locally, reducing systemic side effects. The funding will support clinical trials in the UAE starting Q2 2025, as well as product development and manufacturing scale-up.
“Together, we are working towards a future where localised cancer treatment becomes the global standard,” said Khatija Ali, CEO and Founder of BioSapien. Michael Lints, Partner at Golden Gate Ventures MENA, added: “This investment supports a groundbreaking technology and reinforces the Gulf region’s role in healthcare innovation.”
MediChip™ targets colorectal cancer initially, with future applications for pancreatic and lung cancer, and potential in opioids, hormones, biologics, and gene therapies. BioSapien’s mission is to treat over one million patients by 2035, positioning itself at the forefront of precision drug delivery in oncology.
